Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11388489 | 0.84 | SMN1; SMN2 (0.42) | TDP1HPGDTSHRLMNATP53 | |
| SCHEMBL28439957 | 0.83 | TDP1 (0.44) | TDP1HPGDHSD17B10ALOX15TSHR | |
| SCHEMBL28437577 | 0.83 | TDP1 (0.44) | TDP1HPGDHSD17B10ALOX15TSHR | |
| SCHEMBL5694473 | 0.82 | TSHR (0.64) | TDP1TSHRLMNATP53ALDH1A1 | |
| SCHEMBL28438469 | 0.82 | TDP1 (0.46) | TDP1HPGDHSD17B10ALOX15TSHR | |
| SCHEMBL6938579 | 0.82 | TDP1 (0.41) | TDP1HPGDHSD17B10ALOX15TSHR | |
| SCHEMBL5012212 | 0.82 | TDP1 (0.41) | TDP1HPGDHSD17B10ALOX15TSHR | |
| Mannitol SCHEMBL21522526 | 0.80 | LMNA (0.69) | TDP1HPGDHSD17B10ALOX15TSHR | |
| Mannitol SCHEMBL21522528 | 0.80 | LMNA (0.69) | TDP1HPGDHSD17B10ALOX15TSHR | |
| SCHEMBL7605933 | 0.79 | HPGD (0.50) | TDP1HPGDHSD17B10ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3697774-A1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3654969-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2020-05-27 | — | — | EP | disclosed |
| WO-2019079760-A1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019018395-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2019018353-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-24 | — | — | WO | disclosed |
| US-7151084-B2 | Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes | MILLER LANDON C G | 2006-12-19 | — | — | US | disclosed |
| US-20060142181-A1 | Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes | MILLER LANDON C | 2006-06-29 | — | — | US | disclosed |
| EP-0783306-A4 | METHOD FOR IMPROVING REPRODUCTIVE EFFICIENCY IN FARM ANIMALS | MERCK & CO INC (US) | 1998-09-23 | — | — | EP | disclosed |
| EP-0783306-A1 | METHOD FOR IMPROVING REPRODUCTIVE EFFICIENCY IN FARM ANIMALS | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0708765-A4 | SUBSTITUTED PIPERAZINYLCAMPHOR DERIVATIVES AS OXYTOCIN ANTAGONISTS | MERCK & CO INC (US) | 1996-06-26 | — | — | EP | disclosed |
| WO-1996009824-A1 | METHOD FOR IMPROVING REPRODUCTIVE EFFICIENCY IN FARM ANIMALS | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
| WO-1996008239-A1 | USE OF 5-ALPHA-REDUCTASE INHIBITORS TO INCREASE HDL CHOLESTEROL LEVELS | MERCK & CO., INC. (US) | 1996-03-21 | — | — | WO | disclosed |
| EP-0663827-A4 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS. | MERCK & CO INC (US) | 1995-11-15 | — | — | EP | disclosed |
| WO-1995019773-A1 | CARBOSTYRIL OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-07-27 | — | — | WO | disclosed |
| EP-0663827-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1995-07-26 | — | — | EP | disclosed |
| WO-1995002607-A1 | 7-SUBSTITUTED-Δ4-6-AZASTEROID DERIVATIVES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| WO-1995002587-A1 | SUBSTITUTED PIPERAZINYLCAMPHOR DERIVATIVES AS OXYTOCIN ANTAGONISTS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| WO-1994021614-A1 | SUBSTITUTED 3-PHENANTHRIDINONE DERIVATIVES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| WO-1994007496-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-04-14 | — | — | WO | disclosed |
| WO-1993006092-A1 | PIPERAZINYL (SULFONYL)AMIDE DERIVATIVES OF CAMPHOR AS OXYTOCIN ANTAGONISTS | MERCK & CO., INC. (US) | 1993-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142181-A1 | Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes | VIP, GIPR, GRPR | TDP1 2903/4885HPGD 1786/4885HSD17B10 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.